Patent · US Active

Inhibiting human integrin (alpha-4) (beta-7)

US11370773B1 · kind B1 · utility

2Cited by

20References

24Claims

0Family size

Assignee

Morphic Therapeutic, Inc. · US

Inventors

Matthew G. Bursavich · Tuckahoe, US
Dan Cui · Cambridge, US
James E. Dowling · Lexington, US
Kristopher N. Hahn · Medford, US
Bryce A. Harrison · Framingham, US
Fu-Yang Lin · Sudbury, US
Blaise S. Lippa · Newton, US
Bruce N. Rogers · Belmont, US
Dawn M. Troast · Bedford, US
Cheng Zhong · Belmont, US
Kyle D. Konze · New York, US
Aleksey I. Gerasyuto · Flemington, US
Byungchan Kim · West New York, US
Salma Rafi · Lexington, US
Tyler Day · New York, US
Eugene Richard Hickey · Danbury, US
Evelyne Houang · Queens, US
Robert Zahler · Pennington, US

Key dates

Filing date	Jul 16, 2021
Grant date	Jun 28, 2022
Priority date	—
Expiry date	Jul 16, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D213/64
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

Disclosed are small molecule antagonists of human α4β7 integrin, and methods of using them to treat a number of diseases and conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.